

## Supplementary Online Content

Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. *JAMA Internal Medicine*. Published online April 7, 2014. doi:10.1001/jamainternmed.2014.594.

**eMethod 1. Assessment of Erectile Dysfunction (ED)**

**eMethod 2. Melanoma-Associated Factors**

**eReferences for eMethods 1 and 2**

**eTable 1. The Hazard Ratio (HR) of Incident Melanoma, Squamous Cell Carcinoma (SCC), and Basal Cell Carcinoma (BCC) Associated With Ever Use of Sildenafil in the Past, HPFS 2000-2010**

**eTable 2. The HR of Incident Melanoma, SCC, and BCC Associated With Use of Sildenafil, HPFS 2000-2010, Excluding Subjects With Major Chronic Diseases at Baseline**

**eTable 3. The HR of Incident Melanoma Associated With Ability to Have and Maintain an Erection, HPFS 2000-2010**

This supplementary material has been provided by the authors to give readers additional information about their work.

## **eMethod 1. Assessment of Erectile Dysfunction (ED)**

In 2000, the participants were also asked to rate their ability before 1986, 1986-1989, 1990-1994, 1995-2000, and during the past 3 months, without treatment, to have and maintain an erection adequate for intercourse. Response options included very poor, poor, fair, good and very good. Men with poor or very poor ability at or before 2000 were considered to have ED. The accuracy of a single assessment for ED has been reported extensively. A pilot study among 2072 healthy HPFS participants found that scores on the UCLA Prostate Cancer Index sexual function scale were highly correlated with the single question from that scale assessing erectile function (Pearson and Spearman  $r = 0.90$ ).<sup>1-2</sup> In addition, in a validation study of 137 men aged 55-85 years in Massachusetts Male Aging Study, ED measured by a self-reported single question, which is very similar to our question, was closely correlated with the results of an independent urologic examination (Spearman  $r = 0.80$ ), which was composed of four major components (a physical examination, detailed sexual history, medical history, and psychosocial history). Receiver operating curve analysis showed that the self-reported ED can accurately predict the clinician-diagnosed ED (area under the curve = 0.89)<sup>3</sup>.

## **eMethod 2. Melanoma-Associated Factors**

The positive associations of melanoma risk with older age, male sex, family history of melanoma, higher number of moles, history of severe sunburn, childhood burn reaction to sun, light hair color, higher sun exposure, and higher UV index of residence have been indicated consistently in previous studies<sup>4-6</sup>. Smoking was associated with a decreased risk of melanoma in the HPFS and in a meta-analysis<sup>7</sup>. Body mass index was found to be inversely associated with non-melanoma skin cancer in the HPFS and no association was found for melanoma<sup>8</sup>. However, a recent meta-analysis found a significantly increased risk of melanoma associated with overweight and obese in males<sup>9</sup>. In one recent study in the HPFS, physical activity was associated with a statistically significantly increased risk of both SCC and BCC, and a non-significantly increased risk of melanoma<sup>8</sup>.

In the prospective analysis for the association between sildenafil use and risk of melanoma, multivariate Cox-regression models were adjusted for age (continuous variable), body mass index (<24.9, 25-29.9, or  $\geq 30$  kg/m<sup>2</sup>), smoking (never, past, or current), physical activity (in quintiles, metabolic equivalent hours/wk), childhood reaction to sun (tan without burn, burn, or painful burn/blisters), times of sunburns (0, 1-2, 3-5, or  $\geq 6$ ), mole count (0, 1-2, 3-5, or  $\geq 6$ ), hair color (red, blonde, light brown, or dark brown/black), family history of melanoma (yes or no), sun exposures at high school, age 25-35, age 36-59, and age  $\geq 60$  (<5, 6-10, or  $\geq 11$  hours for each), UV index at birth, age 15, and age 30 ( $\leq 5$ , 6, or  $\geq 7$ ), as well as other treatment for erectile function problems. An indicator variable was created for the missing category of each covariate. Comparing the age-adjusted HR and the multivariate-adjusted HR, adjusting for covariates only led to a slightly decrease in the effect estimates, but no material change of the associations.

## eReferences for eMethods 1 and 2

1. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care*. Jul 1998;36(7):1002-1012.
2. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. *Ann Intern Med*. Aug 5 2003;139(3):161-168.
3. O'Donnell AB, Araujo AB, Goldstein I, McKinlay JB. The validity of a single-question self-report of erectile dysfunction. Results from the Massachusetts Male Aging Study. *J Gen Intern Med*. Jun 2005;20(6):515-519.
4. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. *J Clin Oncol*. Apr 20 2005;23(12):2669-2675.
5. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. *Int J Epidemiol*. Dec 2006;35(6):1514-1521.
6. Walls AC, Han J, Li T, Qureshi AA. Host Risk Factors, Ultraviolet Index of Residence, and Incident Malignant Melanoma In Situ Among US Women and Men. *Am J Epidemiol*. Apr 11 2013.
7. Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. *Int J Epidemiol*. Dec 2012;41(6):1694-1705.
8. Pothiwala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US Caucasians. *Cancer Causes Control*. May 2012;23(5):717-726.
9. Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies. *Eur J Cancer*. Feb 2013;49(3):642-657.

**eTable 1. The Hazard Ratio (HR) of Incident Melanoma, Squamous Cell Carcinoma (SCC), and Basal Cell Carcinoma (BCC) Associated With Ever Use of Sildenafil in the Past, HPFS 2000-2010**

	Person-Years	Cases	Age-adjusted HR (95% CI)	Multivariate-adjusted HR (95% CI) <sup>a</sup>
<b>Melanoma</b>				
No-use	192 053	125	1.00	1.00
Use	12 817	17	2.04 (1.22-3.40)	1.92 (1.14-3.22)
<b>SCC</b>				
No-use	188 863	544	1.00	1.00
Use	12 567	36	0.85 (0.61-1.19)	0.77 (0.55-1.09)
<b>BCC</b>				
No-use	188 863	2806	1.00	1.00
Use	12 567	224	1.11 (0.97-1.28)	1.06 (0.93-1.22)

<sup>a</sup>Adjusted for age (continuous variable), body mass index (<24.9, 25-29.9, or ≥30 kg/m<sup>2</sup>), smoking (never, past, or current), physical activity (in quintiles, metabolic equivalent hours/wk), childhood reaction to sun (tan without burn, burn, or painful burn/blisters), times of sunburns (0, 1-2, 3-5, or ≥6), mole count (0, 1-2, 3-5, or ≥6), hair color (red, blonde, light brown, or dark brown/black), family history of melanoma (yes or no), sun exposures at high school, age 25-35, age 36-59, and age ≥60 (<5, 6-10, or ≥11 hours for each), UV index at birth, age 15, and age 30 (≤5, 6, or ≥7), as well as other treatment for erectile function problems.

**eTable 2. The Hazard Ratio (HR) of Incident Melanoma, SCC, and BCC Associated With Use of Sildenafil, HPFS 2000-2010, Excluding Subjects With Major Chronic Diseases at Baseline**

	Person-Years	Cases	Age-adjusted HR (95% CI)	Multivariate-adjusted HR <sup>a</sup> (95% CI)
<b>Melanoma</b>				
No-use	113 515	70	1.00	1.00
Use	5774	9	2.37 (1.17-4.77)	2.24 (1.05-4.78)
<b>SCC</b>				
No-use	111 692	291	1.00	1.00
Use	5676	14	0.80 (0.47-1.37)	0.80 (0.46-1.37)
<b>BCC</b>				
No-use	111 692	1631	1.00	1.00
Use	5676	89	1.00 (0.80-1.24)	1.05 (0.84-1.30)

<sup>a</sup> Adjusted for age (continuous variable), body mass index (<24.9, 25-29.9, or ≥30 kg/m<sup>2</sup>), smoking (never, past, or current), physical activity (in quintiles, metabolic equivalent hours/wk), childhood reaction to sun (tan without burn, burn, or painful burn/blisters), times of sunburns (0, 1-2, 3-5, or ≥6), mole count (0, 1-2, 3-5, or ≥6), hair color (red, blonde, light brown, or dark brown/black), family history of melanoma (yes or no), sun exposures at high school, age 25-35, age 36-59, and age ≥60 (<5, 6-10, or ≥11 hours for each), UV index at birth, age 15, and age 30 (≤5, 6, or ≥7), as well as other treatment for erectile function problems.

**eTable 3. The Hazard Ratio (HR) of Incident Melanoma Associated With Ability to Have and Maintain an Erection, HPFS 2000-2010<sup>a</sup>**

	Person-Years	Cases	Age-adjusted HR (95% CI)	Multivariate-adjusted HR (95% CI) <sup>b</sup>
Very good	56 196	39	1.00	1.00
Good	39 399	22	0.79 (0.46-1.33)	0.76 (0.45-1.30)
Fair	23 649	15	0.85 (0.46-1.58)	0.86 (0.46-1.61)
Erectile dysfunction	36 706	29	1.02 (0.58-1.80)	1.03 (0.57-1.85)

<sup>a</sup> Users of sildenafil and other treatments for erectile function problems were excluded.

<sup>b</sup> Adjusted for age (continuous variable), body mass index (<24.9, 25-29.9, or ≥30 kg/m<sup>2</sup>), smoking (never, past, or current), physical activity (in quintiles, metabolic equivalent hours/wk), childhood reaction to sun (tan without burn, burn, or painful burn/blisters), times of sunburns (0, 1-2, 3-5, or ≥6), mole count (0, 1-2, 3-5, or ≥6), hair color (red, blonde, light brown, or dark brown/black), family history of melanoma (yes or no), sun exposures at high school, age 25-35, age 36-59, and age ≥60 (<5, 6-10, or ≥11 hours for each), UV index at birth, age 15, and age 30 (≤5, 6, or ≥7).